Concurrent epirubicin and trastuzumab use increases complete pathological response rate without additional cardiotoxicity in patients with human epidermal growth factor receptor 2‐positive early breast cancer: A meta‐regression analysis

Concurrent epirubicin and trastuzumab use increases complete pathological response rate without additional cardiotoxicity in patients with human epidermal growth factor receptor 2‐positive early breast cancer: A meta‐regression analysis

Abstract Background Due to cardiotoxicity concerns, the concurrent use of epirubicin and trastuzumab has not been fully studied. This study aimed to examine the cardiotoxicity and pathological complete response (pCR) rate associated with the concurrent regimens in patients with human epidermal growt...

Full description

Saved in:
Bibliographic Details
Main Authors: Ming‐Han Yang, Chiun‐Sheng Huang, Dwan‐Ying Chang, Fu‐Chang Hu, Shu‐Min Huang, Po‐Hsiang Huang, I‐Chun Chen, Tom Wei‐Wu Chen, Ching‐Hung Lin, Yen‐Shen Lu
Format: Article
Language:English
Published: Wiley 2024-07-01
Series:Cancer Medicine
Subjects:
cardiotoxicity
early breast cancer
epirubicin
human epidermal growth factor receptor 2
trastuzumab
Online Access:https://doi.org/10.1002/cam4.70005
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/cam4.70005

Similar Items